Injectable Biologics: What Is the Evidence?

ABSTRACTInjectable biologics have attracted considerable interest in the field of musculoskeletal medicine. Biologics encompass a broad and diverse group of human tissue–derived therapeutics. The most commonly reported biologics for use in musculoskeletal conditions include platelet-rich plasma, bon...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of physical medicine & rehabilitation Vol. 99; no. 10; pp. 950 - 960
Main Authors:	Kubrova, Eva, D’Souza, Ryan S., Hunt, Christine L., Wang, Qian, van Wijnen, Andre J., Qu, Wenchun
Format:	Journal Article
Language:	English
Published:	United States Lippincott Williams & Wilkins 01-10-2020 Copyright Wolters Kluwer Health, Inc. All rights reserved
Subjects:	Biological Products - administration & dosage Biological Products - therapeutic use Evidence-Based Medicine Humans Injections Musculoskeletal Diseases - drug therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACTInjectable biologics have attracted considerable interest in the field of musculoskeletal medicine. Biologics encompass a broad and diverse group of human tissue–derived therapeutics. The most commonly reported biologics for use in musculoskeletal conditions include platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stem cells, microfragmented fat, stromal vascular fraction, amniotic membrane–based products, and autologous conditioned serum. The benefits of biologics in tissue healing and regeneration are thought to be derived from their trophic, paracrine, and immunomodulatory functions. The purpose of this review is to define commonly used injectable biologics and to appraise current evidence on its efficacy in the treatment of musculoskeletal disease.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0894-9115 1537-7385
DOI:	10.1097/PHM.0000000000001407